Etravirine
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE
Also known as: etravirin, intelence, R-165335, TMC-125
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Etravirine is an ofp drug in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2008. Its mechanism of action is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inducers. DrugCentral lists 10 molecular targets, including pol, gag-pol and reverse transcriptase. Recorded indications include Human immunodeficiency virus infection.
- Approval status: ofp (first approved 2008 by the FDA).
- Drug class: Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor.
- Mechanism of action: Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inducers.
- Molecular targets: pol, gag-pol, reverse transcriptase and reverse transcriptas (10 listed in DrugCentral).
- Indications: Human immunodeficiency virus infection.
- ATC code: J05AG04 (Non-nucleoside reverse transcriptase inhibitors).
- Molecular formula: C20H15BrN6O; molecular weight 435.29 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Human immunodeficiency virus infection
Contraindications (5)
- Breastfeeding (mother)
- Chronic hepatitis C
- Chronic type B viral hepatitis
- Liver function tests abnormal
- Peripheral nerve disease
Mechanism & targets
| Mechanism of action (MoA) | Cytochrome P450 2C19 Inhibitors; Cytochrome P450 2C9 Inhibitors; Cytochrome P450 3A Inducers; Non-Nucleoside Reverse Transcriptase Inhibitors; P-Glycoprotein Inhibitors |
|---|---|
| Established pharmacologic class | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor |
Molecular targets (10)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Reverse transcriptase/RNaseH | pol | inhibitor | IC50 9.22 |
| Gag-Pol polyprotein | gag-pol | unknown | IC50 9.00 |
| Reverse transcriptase protein | reverse transcriptase | unknown | IC50 8.89 |
| Reverse transcriptase | reverse transcriptas | unknown | IC50 8.00 |
| Cruzipain | — | unknown | IC50 5.40 |
| Canalicular multispecific organic anion transporter 2 | ABCC3 | unknown | IC50 5.29 |
| ATP-binding cassette sub-family G member 2 | ABCG2 | unknown | IC50 5.22 |
| Multidrug resistance protein 1 | ABCB1 | unknown | IC50 5.12 |
| Canalicular multispecific organic anion transporter 1 | ABCC2 | unknown | IC50 5.11 |
| Multidrug resistance-associated protein 1 | ABCC1 | unknown | IC50 5.07 |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2008-08-28 | EMA | — | — | |
| 2008-01-18 | FDA | — | JANSSEN R AND D |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
J05AG04 | ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Non-nucleoside reverse transcriptase inhibitors |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Virologic failure | 987.7 |
| Lipodystrophy acquired | 736.5 |
| Viral mutation identified | 637.7 |
| Progressive external ophthalmoplegia | 488.3 |
| Mitochondrial toxicity | 486.2 |
| Drug resistance | 467.1 |
| Pathogen resistance | 428.3 |
| Eyelid ptosis | 335.8 |
| CD4/CD8 ratio decreased | 295.6 |
| CD4 lymphocytes decreased | 257.7 |
| Drug interaction | 253.0 |
| Enlarged clitoris | 207.3 |
Chemical structure
| Molecular formula | C20H15BrN6O |
|---|---|
| Molecular weight | 435.29 g/mol |
| CAS number | 269055-15-4 |
| InChIKey | PYGWGZALEOIKDF-UHFFFAOYSA-N |
| PubChem CID | 193962 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Etravirine used for?
DrugCentral lists the following indications for Etravirine: Human immunodeficiency virus infection.
How does Etravirine work?
Etravirine is classified as Cytochrome P450 2C19 Inhibitors, Cytochrome P450 2C9 Inhibitors and Cytochrome P450 3A Inducers; its molecular targets in DrugCentral include pol (inhibitor), gag-pol, reverse transcriptase and reverse transcriptas.
When was Etravirine first approved?
Etravirine was first approved by the FDA in 2008.
What drug class does Etravirine belong to?
Etravirine is in the Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor class.
What is the chemical formula of Etravirine?
Etravirine has the molecular formula C20H15BrN6O and a molecular weight of 435.29 g/mol.
Browse: all drugs starting with E · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1115 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL308954 — compound record and bioactivity
- PubChem CID 193962 — chemical identifiers
- DrugBank DB06414 — drug record
- FDA UNII 0C50HW4FO1 — substance identity
- DailyMed: FDA labels for Etravirine — current prescribing information (label search)
- UniProt O15438 (ABCC3) — target protein
- UniProt Q9UNQ0 (ABCG2) — target protein
- UniProt P08183 (ABCB1) — target protein
- UniProt Q92887 (ABCC2) — target protein
- UniProt P33527 (ABCC1) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.